SOBREPIN ® Sobrerol

SOBREPIN® is a Sobrerol based drug

THERAPEUTIC GROUP: Mucolytics

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications SOBREPIN ® Sobrerol

SOBREPIN® is used in the treatment of respiratory diseases characterized by thick and viscous mucus.

Mechanism of action SOBREPIN ® Sobrerol

SOBREPIN® is a drug based on Sobrerol, an active ingredient characterized by a classic terpene structure, endowed with an imposing mucolytic and mucoregulatory action.

Taken orally, in fact, the drug is rapidly absorbed from the gastro-enteric tract, concentrating in bronchial secretions already after 60 minutes and persisting for over 3 hours, after which, after hepatic metabolism, it is excreted in the form of inactive metabolites via the kidney.

The mucoregulatory action is determined by the rheological properties of the active ingredient, which once it reaches the respiratory environment, draws water, hydrating the mucus and significantly reducing its viscosity.

All this also favors an increase in the mucociliary activity of the respiratory epithelium, thus allowing a more effective elimination of sputum, which will obviously appear less dense and viscous.

Studies carried out and clinical efficacy

SOBREROL AND PULMONARY HYPERTENSION

Int Arch Allergy Immunol. 1995 May-Jun; 107 (1-3): 272-4.

Experimental study demonstrating how treatment with Sobrerol can improve interstitial fibrosis and reduce the risk of pulmonary hypertension

SOBREROL IN RESPIRATORY INFLAMMATORY DISEASES

Respiration. 1986; 50 (3): 202-17.

Interesting study that demonstrates how the use of mucolytics like Sobrerol can reduce the incidence and severity of episodes of re-exacerbation of chronic inflammatory respiratory pathologies, thus improving the quality of life of affected patients.

SOBREROL AND PHYSICAL CHEMICAL PROPERTIES OF BRONCHIAL SECRETIONS

Respiration. 1981; 42 (2): 105-9.

A dated study that demonstrates how Sobrerol therapy can significantly improve the rheological characteristics of bronchial secretions in patients suffering from chronic respiratory diseases, also guaranteeing a clear improvement in mucociliary clearance.

Method of use and dosage

SOBREPIN®

Sobrerol 40 mg syrup per 5 ml of product.

Granulated for 300 mg oral suspension of Sobrerol.

Dosages and timing of intake provided for SOBREPIN® must be established by your doctor based on the patient's clinical characteristics.

As a rule, in adults it is recommended to take 2 sachets a day, to be dissolved in a glass of water or 10-20 ml of syrup twice a day.

Warnings SOBREPIN ® Sobrerol

The intake of SOBREPIN® should be preceded by a careful medical examination aimed at clarifying the prescriptive appropriateness and evaluating the possible presence of contraindications to the use of the drug.

Particular caution in the use of SOBREPIN® should in fact be provided by patients suffering from severe liver and kidney diseases, given the compromised metabolic capacity.

The same caution should be reserved for patients with reduced expectoration capacity, given the important increase in sputum volume, which could induce bronchial obstruction.

SOBREPIN® in granules contains aspartame and sorbitol, making it therefore contraindicated in patients with fructose intolerance, glucose-galactose malabsorption, sucrase-isomaltase insufficiency and phenylketonuria.

SOBREPIN® in syrup contains ethanol, therefore contraindicated in pediatric and sports patients, and parahydroxybenzoates, excipients with strong allergizing power.

PREGNANCY AND BREASTFEEDING

The absence of studies able to test the safety profile of Sobrerol for the health of the fetus and infant, extend the aforementioned contraindications to the use of SOBREPIN® also to pregnancy and the subsequent period of breastfeeding.

Interactions

At the moment active ingredients capable of interfering with Sobrerol are not known.

Contraindications SOBREPIN ® Sobrerol

SOBREPIN® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients and in patients below 2 years of age.